Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Etherna Immunotherapies N.V.

Headquarters: Niel, Belgium
Year Founded: 2013
Status: Private

BioCentury | Feb 7, 2025
Discovery & Translation

Science Spotlight: New protein degradation mechanism

BioCentury’s roundup of translational innovations also includes new insight into repeat expansion in Huntington’s and 10 new products
BioCentury | Sep 13, 2024
Data Byte

PanTera largest Belgian A round to date

Only nine other biotechs have raised over $25 million since 2015
BioCentury | Jul 10, 2024
Management Tracks

Pfizer seeking successor as Dolsten prepares to step down from R&D role

Plus: Lexicon, Pathios and Xeris name new CEOs, and updates from Jazz, AgomAb, VectorY, eTheRNA and more
BioCentury | Oct 18, 2023
Management Tracks

eTheRNA names Sagaert CEO, Dekkers as chairman

Plus: Cyrus Harmon becomes CEO at Vilya, and updates from Epic Bio, Exscientia, Pliant, Cognito, Pattern
BioCentury | Sep 8, 2023
Management Tracks

Greig named non-executive chair at Nucleome

Plus: updates from SparX, Breathe, Find and MedinCell
BioCentury | Jun 8, 2023
Management Tracks

New CFO, commercial officer at Pulmocide

Plus: Helmling named CBO at eTheRNA, and updates from EpimAb, Ring, Amarna, XNK and more
BioCentury | Dec 15, 2022
Management Tracks

Debra Yu leaving LianBio

Plus: Bayer vet Weinand appointed chair at Umoja, and updates from vTv, Gradalis, Generate and more
BioCentury | Oct 19, 2022
Management Tracks

New chairs at SomaLogic, Anjarium

Plus Dechamps becomes CEO at Bioxodes, and updates from Abalos, M2Gen and Orion
BioCentury | Aug 23, 2022
Regulation

Aug. 23 Quick Takes: Clinical hold sinks Foghorn

Plus Third Harmonic consider IPO, eTheRNA raises €39M and updates from Gate, Freedom and more
BioCentury | Feb 4, 2022
Product Development

Feb. 3 Quick Takes: Roche culls its oncology pipeline

Plus eTheRNA, Merck KGaA in mRNA deal, Novavax scores another approval and more
Items per page:
1 - 10 of 23